Eudaimonia Asset Management plans to offer an ultra micro cap growth, micro cap growth, and small cap growth products marketed to institutional and high-net worth investors worldwide. The firm anticipates launching its first products in the 4th quarter of 2007.
The firm’s founders have more than 20 years of combined experience in small and micro-cap investing while at Nicholas-Applegate, a San Diego firm founded in 1984 and now part of the Allianz Group, according to a press release. The founders of the new firm are :
- Travis T. Prentice, a former partner, managing director and lead portfolio manager for Nicholas-Applegate’s Micro Cap and Ultra Micro Cap strategies;
- Montie L. Weisenberger, who was a senior vice president and lead portfolio manager for Nicholas-Applegate’s Traditional Small-to-Mid Cap investment strategy; and
- Joshua M. Moss, who was a vice president and research analyst on Nicholas-Applegate’s Micro and Ultra Micro Cap strategies.
Eudaimonia – a classic Greek word that Aristotle described as achieving a unique state of human or life flourishing – being happy, healthy and prosperous and virtuous throughout one’s life, according to a press release – will be based in Encinitas, in the north coast area of San Diego County. The name was chosen to symbolize the philosophy of the firm’s founders about the desired goal for their investors.
In the press release, Prentice said Eudaimonia has selected Roth Capital Partners LLC (ROTH), of Newport Beach, as its financial partner. ROTH is a full-service investment bank focused on the small and micro-cap markets. It offers a range of investment banking services, including raising capital, merger and acquisition advisory services, research, institutional sales and trading, as well as investor conferences. It has raised over $10 billion for small and micro-cap public companies and completed over 135 merger, acquisition and advisory assignments.
Eudaimonia Asset Management is in the process of seeking registration as an investment adviser with the U.S. Securities and Exchange Commission.
For further information, see www.eudaimonia-invest.com , or call 760-519-1508.
« Biotech Lead Directors See One-third Increase in Compensation